ASX-listed digital health company ResApp Health has received TGA approval to list its new wearable device for monitoring cough on the Australian Register of Therapeutic Goods (ARTG).
The device, which has also received CE Mark certification allowing it to be manufactured and sold in Europe, is initially aimed at the clinical trial market to measure cough frequency but is also expected to be used as a platform for monitoring at-risk patients with COPD or asthma.
